Related Experiment Video
Updated: Mar 21, 2026

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
[Small molecular agents against MERS-CoV infection]
Abstract:
Middle East respiratory syndrome coronavirus (MERS-CoV) has caused outbreaks of SARS-like disease with 35% case-fatality rate, mainly in the Middle East. A more severe outbreak of MERS occurred recently in the Republic of Korea, where 186 people contracted the infections, causing great concern worldwide. So far, there has been no clinically available drug for the treatment of MERS-CoV infection. The potential drugs against MERS-CoV mainly consist of monoclonal antibodies, peptides and small molecular agents. Small molecular agents have an advantage of easier synthesis, lower cost in production and relatively higher stability. There is better chance for those candidates to gain a quick development. This article reviews the progress of developing small molecular MERS-CoV agents.
Insights
Developing small molecular agents offers a promising avenue for treating Middle East respiratory syndrome coronavirus (MERS-CoV) infections. These agents are easier to produce and more stable than other potential drugs.
Area of Science:
- Virology
- Drug Discovery
- Infectious Diseases
Background:
- Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory illness with a high fatality rate.
- Recent outbreaks, including one in South Korea, have heightened global concern.
- No clinically approved treatments currently exist for MERS-CoV infection.
Purpose of the Study:
- To review the progress in developing small molecular agents as potential treatments for MERS-CoV.
- To highlight the advantages of small molecular agents in drug development.
Main Methods:
- Literature review of ongoing research and development of small molecular agents against MERS-CoV.
- Analysis of the characteristics and potential of various small molecule candidates.
Main Results:
- Small molecular agents demonstrate advantages in synthesis, cost-effectiveness, and stability.
- Several classes of small molecules are being investigated for MERS-CoV treatment.
- Progress in developing these agents suggests a viable therapeutic strategy.
Conclusions:
- Small molecular agents represent a promising and rapidly developable therapeutic option for MERS-CoV.
- Continued research into small molecule drug candidates is crucial for combating MERS-CoV outbreaks.
More Related Videos
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
07:53A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
Related Concept Videos
Inhibitors of Viral Protein Synthesis
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Anthelminthic Agents
Clinical Significance of Antibiotic Resistance